A wireless device for managing diabetes and obesity
The ECHO device uses platinum-decorated gold nanoclusters to turn blood glucose into gluconate.
Researchers developed an implantable ECHO device for the management of diabesity. Diabesity refers to lifestyle-related type 2 diabetes and associated obesity.
The ECHO device contains platinum-decorated gold nanoclusters embedded in graphite felt. It uses wireless, low-power activation of volts and milliamperes.
The device enables selective, electrically tunable oxidation of blood glucose to renally cleared gluconate. This process is electrocatalytic.
In type 2 diabetic mice, the device restored glucose homeostasis within hour. It also shifted metabolism from glucose to lipid utilization.
Treatment for weeks reduced body weight and triglycerides. It increased circulating free fatty acids and ketone bodies without detectable hypoglycemia.
The ECHO device can couple to a commercial continuous glucose monitoring system. This enables autonomous, smartphone-controlled, drug-free closed-loop management.
Key facts
- Diabesity affects more than billion people worldwide.
- The ECHO device uses volts and milliamperes for activation.
- The device converts blood glucose to renally cleared gluconate.